subjects chronically infected with hcv genotype 1

non-responder to prior therapy with peginterferon alfa and ribavirin

hcv rna viral load of ≥ 100,00 iu/ml

results of a liver biopsy ≤ 24 months prior to randomization consistent with chronic hcv infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics will be capped at 10% of randomized study population)

ultrasound, ct scan or mri results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma

body mass index (bmi) of 18 to 35 kg/m2

positive for hepatitis b infection (hbsag) or hiv-1/hiv-2 antibody at screening

evidence of medical condition associated with chronic liver disease other than hcv

evidence of decompensated cirrhosis based on radiologic criteria or biopsy